Dr. Novack was invited to speak at the American Society for Cataract and Refractive Surgery in Boston, MA. He spoke in the Innovator’s Symposium on “Better Therapeutics in Glaucoma Through Drug Delivery”. www.ascrs.org
Dr. Novack’s presentations in 2014 include: FDA requirements for new drugs at Glaucoma 360 (Glaucoma Research Foundation), “Better Therapeutics in Glaucoma Through Drug Delivery” in the Innovator’s symposium at the American Society for Cataract & Refractive Surgery, and a Phase 2b study of AR-13324 in glaucoma and ocular hypertension at ARVO.
Dr. Novack continues to advise numerous companies on FDA interactions, including critical End of Phase 2 meetings, with frequent meetings with the FDA. Numerous investment firms have asked Dr. Novack’s advise on investments in innovative ophthalmic firms.
Dr. Novack was invited to speak at the European Glaucoma Society meeting in Copenhagen in June 2012 on the issue of generic drugs.
Dr. Novack was an invited speaker at the ARVO Annual Meeting in Fort Lauderdale in May 2012 at a symposium on Off Label Use. Panelists included leading academic and FDA experts.
In 2011, Dr. Novack was invited to speak on ophthalmic drug development on several international panels which included senior FDA ophthalmic personnel. These were:
- Ophthalmology Innovation Summit (Orlando, FL)
- Glaucoma sub-specialty day at the American Academy of Ophthalmology (Orlando, FL
- International Symposium on Ocular Pharmacology and Therapeutics (Vienna, Austria) www.isopt.net
He also participated in the first ophthalmology workshop of the European Medicines Agency (London, UK).